228 related articles for article (PubMed ID: 30246661)
1. [Alarmins and anti-alarmin biologics in asthma].
Görgülü B; Bavbek S
Tuberk Toraks; 2018 Jun; 66(2):166-175. PubMed ID: 30246661
[TBL] [Abstract][Full Text] [Related]
2. Sounding the alarmins-The role of alarmin cytokines in asthma.
Gauvreau GM; Bergeron C; Boulet LP; Cockcroft DW; Côté A; Davis BE; Leigh R; Myers I; O'Byrne PM; Sehmi R
Allergy; 2023 Feb; 78(2):402-417. PubMed ID: 36463491
[TBL] [Abstract][Full Text] [Related]
3. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
Porsbjerg CM; Sverrild A; Lloyd CM; Menzies-Gow AN; Bel EH
Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32586879
[TBL] [Abstract][Full Text] [Related]
4. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma.
Chan R; Stewart K; Misirovs R; Lipworth BJ
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1497-1505. PubMed ID: 35131510
[TBL] [Abstract][Full Text] [Related]
5. Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response.
Duchesne M; Okoye I; Lacy P
Front Immunol; 2022; 13():975914. PubMed ID: 36311787
[TBL] [Abstract][Full Text] [Related]
6. Anti-alarmin approaches entering clinical trials.
Gauvreau GM; White L; Davis BE
Curr Opin Pulm Med; 2020 Jan; 26(1):69-76. PubMed ID: 31408015
[TBL] [Abstract][Full Text] [Related]
7. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD.
Calderon AA; Dimond C; Choy DF; Pappu R; Grimbaldeston MA; Mohan D; Chung KF
Eur Respir Rev; 2023 Mar; 32(167):. PubMed ID: 36697211
[TBL] [Abstract][Full Text] [Related]
8. Epithelial alarmins: a new target to treat chronic respiratory diseases.
Nedeva D; Kowal K; Mihaicuta S; Guidos Fogelbach G; Steiropoulos P; Jose Chong-Neto H; Tiotiu A
Expert Rev Respir Med; 2023; 17(9):773-786. PubMed ID: 37746733
[TBL] [Abstract][Full Text] [Related]
9. Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma.
Mitchell PD; O'Byrne PM
Pharmacol Ther; 2017 Jan; 169():104-112. PubMed ID: 27365223
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
Pelaia C; Pelaia G; Longhini F; Crimi C; Calabrese C; Gallelli L; Sciacqua A; Vatrella A
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572294
[TBL] [Abstract][Full Text] [Related]
11. The Role of Airway Epithelial Cell Alarmins in Asthma.
Whetstone CE; Ranjbar M; Omer H; Cusack RP; Gauvreau GM
Cells; 2022 Mar; 11(7):. PubMed ID: 35406669
[TBL] [Abstract][Full Text] [Related]
12. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.
Salvati L; Maggi L; Annunziato F; Cosmi L
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):590-596. PubMed ID: 34608100
[TBL] [Abstract][Full Text] [Related]
13. Airway epithelial type-2 alarmin profiles: Blood eosinophil counts remain in memory.
Vernisse C; Tuaillon E; Suehs C; Gras D; Bedin AS; Charriot J; Knabe L; Vachier I; Chanez P; Petit A; Bourdin A
Eur J Immunol; 2023 Apr; 53(4):e2250101. PubMed ID: 36793156
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial Causes and Consequences of TLSP Production, Function, and Release in the Asthmatic Airway.
Brister DL; Omer H; Whetstone CE; Ranjbar M; Gauvreau GM
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672419
[TBL] [Abstract][Full Text] [Related]
15. Tezepelumab for asthma.
Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
[TBL] [Abstract][Full Text] [Related]
16. Antialarmins for treatment of asthma: future perspectives.
Al-Sajee D; Oliveria JP; Sehmi R; Gauvreau GM
Curr Opin Pulm Med; 2018 Jan; 24(1):32-41. PubMed ID: 29084017
[TBL] [Abstract][Full Text] [Related]
17. TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation.
Schmitt P; Duval A; Camus M; Lefrançais E; Roga S; Dedieu C; Ortega N; Bellard E; Mirey E; Mouton-Barbosa E; Burlet-Schiltz O; Gonzalez-de-Peredo A; Cayrol C; Girard JP
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38597952
[TBL] [Abstract][Full Text] [Related]
18. S100A alarmins and thymic stromal lymphopoietin (TSLP) regulation in severe asthma following bronchial thermoplasty.
Gagnon PA; Klein M; De Vos J; Biardel S; Côté A; Godbout K; Laviolette M; Laprise C; Assou S; Chakir J
Respir Res; 2023 Nov; 24(1):294. PubMed ID: 37996952
[TBL] [Abstract][Full Text] [Related]
19. Tezepelumab: patient selection and place in therapy in severe asthma.
Menzella F; Munari S; Corsi L; Tonin S; Cestaro W; Ballarin A; Floriani A; Dartora C; Senna G
J Int Med Res; 2024 Apr; 52(4):3000605241246740. PubMed ID: 38676539
[TBL] [Abstract][Full Text] [Related]
20. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
